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Abstract 
 The pathogenesis of inflammatory diseases is deeply influenced by 
environmental factors. Inflammatory bowel disease (IBD) is one of the examples of 
chronic refractory digestive disorder which is influenced by environmental factor. The 
major types of IBD are Crohn's disease (CD) and ulcerative colitis (UC). These disorders 
are categorized based on the site of inflammation, histological findings, and clinical 
symptoms. The most common symptoms are diarrhea, fever, and abdominal pain. The 
pathogenesis of IBD remains unknown. However, a possible cause is dysfunction of the 
immune system. Numerous studies suggested that several factors such as food, smoking, 
and gut microbiota, are involved in the progression of the disease. Although various 
therapeutic approaches are available, most clinical drugs are associated with the 
occurrence of adverse effects. Therefore, the development of a more specific and safe 
treatment options is urgently warranted. 
 Here, the author proposed formulation strategy is one of the important factors 
that maximize the therapeutic effects of natural products. Drug delivery systems (DDS) 
could maximize the value of drug seeds by improving their pharmacokinetic profiles 
and/or pharmacodynamic effects and reducing the incidence of adverse effects. In this 
study, the author demonstrated that liposome, one of the major formulations of DDS, 
could accumulate target inflamed tissue in the lungs and colon through an enhanced 
permeability and retention (EPR) effect. Nanosized particle modification and targetability 
of nanoparticles were focused on both lung and colon injury sites. Previous studies have 
indicated that extracts of natural products have a potential to improve refractory diseases, 
such as neurological diseases, cancer, and inflammatory diseases. Thus, the author wished 
to investigate the usefulness of natural product encapsulation in nanoparticles. Especially, 
several plants derived from North Africa and the Mediterranean have beneficial health 
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effects compared with plants derived from other regions of the world. It has been 
demonstrated that several components of natural products (e.g., polyphenols and 
flavonoids) prevent functional impairment of intestinal epithelial cells and inflammation 
of the lamina propria in experimental IBD model. This is achieved through direct anti-
inflammatory effects and indirectly therapeutic effects, including improvement of the gut 
microbiome environment.  Finally, Apigenin nanoparticle could be manufactured 
successfully, Apigenin and Apigenin nanoparticles showed strong anti- inflammatory 
effects in several genetic markers in LPS-stimulated RAW264.7 cell line model. In 
summary, DDS maximizes the value of drug seeds, the formulation approach of natural 
products for inflammatory disease is attractive strategy. Apigenin nanoparticle is 
promising therapeutic option for these refractory diseases.  
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Chapter 1 Introduction 
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1.1 Inflammatory bowel disease (IBD) and the environment 
Thus far, there is no definitive cause determined for the development of IBD. 
However, numerous studies suggested that several factors (i.e., food, smoking, and gut 
microbiota) are involved in disease progression (Figure 1.1) [1].  
Previous research demonstrated that the Western food pattern may worsen the 
state of digestive tract inflammation[2]. For instance, the Western food pattern contains 
large amounts of refined sugar, omega-6 polyunsaturated fatty acids (PUFAs) and fast 
foods, combined with deficiencies in fruit, vegetables, and fiber [2] . These Western food 
patterns are associated with a serious risk to gut health, namely the provocation of the 
inflammation mediator directory, and dysbiosis of gut microbiota and metabolites in the 
digestive tract. A previous study suggested that high omega-6/omega-3 PUFA ratios may 
be related to the development of IBD [3]. Omega-6 fatty acid is a precursor of arachidonic 
acid and, proinflammatory prostaglandin E2, leukotriene B4, and platelet aggregation 
thromboxane A2. Unlike omega-6 PUFA, omega-3 PUFA is a precursor of anti-
inflammatory prostaglandins E3, which leads to an equilibrium of natural fatty acid ratios 
to reduce the formation of prostaglandin E2 [3]. Notably, several studies have 
demonstrated that the Mediterranean food pattern (35% total fat: 15% monounsaturated 
fatty acids, which are mainly derived from olive oil, 13% saturated fatty acids, and 6% 
PUFAs) exert a beneficial effect against ulcerative colitis (UC), reduction of 
inflammatory cytokines, and normalization of the microbiome [4]. 
In addition, there is increasing evidence regarding the association of smoking 
and IBD. Surprisingly, the effect against the disease state of IBD is completely different 
from those against Crohn's disease (CD) and ulcerative colitis: Smoking cessation 
benefits the improvement of CD, whereas, smoking exerts a protective effect against 
active UC. The mechanism involved in this process is currently poorly understood. 
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Studies reported that nicotine, which is an agonist of the aryl hydrocarbon receptor (AhR), 
has a favorable influence on active UC [5] [6]. Despite the beneficial effect of smoking 
against active UC, the adverse effects linked to this habit are more serious. 
Previous reports demonstrated that exposure to broad-spectrum antibiotics in 
childhood suppresses the normal development of the microbiome [1]. Finally, recent 
investigations have stated that gut microbiota homeostasis plays an important role in the 
function of the gut epithelial barrier and maturation of immune cells. Exposure to 
antibiotics results in the reduction of particular enterobacteria, causing unusual weight 
gain and autoimmune diseases, such as inflammatory bowel disease, asthma, allergies, 
arthritis, and multiple sclerosis [7]. However, several studies highlighted that treatment 
with antibiotics is effective against pouchitis caused by CD [8]. 
Collectively, understanding the association between environmental factors and 
IBD is important in elucidating the etiology and epidemiology of this disorder. 
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Figure 1.1 Schematic diagram of how environmental factors contribute to the 
development of IBD. 
The pathogenesis of inflammatory diseases is deeply influenced by environmental factors, 
such as alternation of microbiome diversity, changing of intestinal permeability and 
elevation of proinflammatory cytokines. 
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1.2 The potential of natural products against digestive disorders 
It has been proposed that extracts from certain kinds of plants ameliorate 
digestive disorders[9]. These ingredients possess antioxidant, anti-inflammatory, and 
anti-cancer properties. For example, polyphenol and flavonoid are extracted from 
Oleaceae olea, and Lamiaceae Dracocephalum have a therapeutic effect against IBD. 
Some plants originating from the Mediterranean or North Africa possess a higher content 
of these ingredients. These active substances include Oleuropein, Apigenin, Luteolin and 
Rosmarinic acid. (Figures 1.2 and 1.3) [9]. In Southeast Asia, Indigo naturalis from 
Persicaria tinctoria is used as herbal medicine against UC, improving the function of the 
mucosal barrier via the IL-22 pathway through activation of AhR. Indigo naturalis 
includes indigo and indirubin molecules, which act as AhR ligands (Figures 1.2 and 1.3) 
[6]. In addition, Prunella vulgaris contains flavonoids (e.g., rosmarinic acid) and has an 
anti-inflammatory effect [10]. As mentioned above, these natural products have been 
widely used for treatment of digestive disorders.  
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Figure 1.2 Plants used in the treatment against IBD. 
Extracts from certain kinds of plants ameliorate digestive disorders. 
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Figure 1.3 Chemical structures of active substances contained in natural products 
with therapeutic effects against IBD. 
Oleuropein, apigenin, luteolin, indirubin and rosmarinic acid possess a therapeutic effect 
against IBD. 
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1.3 Expected benefits of drug delivery systems 
The suitable dose of most active pharmaceutical ingredients (APIs) is 
investigated prior to conducting clinical trials. A drug formulation strategy is required to 
determine the appropriate dosage. In recent decades, the DDS has been developed. The 
three major advantages of the DDS are targeting, controlled release, and improvement of 
absorption. The application of the DDS enhances efficacy, reduces adverse effects, and 
stabilizes ingredients. Nano- or micro-particle formulation is one of the promising 
technologies that can encapsulate drug payloads. A wide variety of therapeutic agents can 
be encapsulated (e.g., compounds, genes, and peptides). Furthermore, size and surface 
modification of the particle is possible to target specific tissues and cells in the body 
(Figure 1.4). Following the intravenous administration of particles, large-size particles 
(~200 nm) tend to accumulate in the spleen and liver, whereas particles <100 nm 
accumulate in the injury site and/or tumor via a leaky vascular wall with the EPR 
(enhanced permeability and retention) effect [12]. Moreover, surface modification of the 
particle realizes more effective delivery to the site of the lesion. In fact, dozens of 
medicines against cancer and infection that have adapted this technology are currently 
available. The most commonly used clinical drug formulation is a liposome that consists 
of lipid bilayers. A major example is liposome-encapsulated doxorubicin, which has been 
approved as an anticancer drug. Another example is liposomal amphotericin B, which is 
used against fungal infections. Both drugs have exhibited high efficacy and reduction of 
adverse effects versus API. 
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Figure 1.4 Expected application of drug delivery systems. 
Nano- or micro-particle formulation is one of the promising technologies that can 
encapsulate drug payloads. A wide variety of therapeutic agents can be encapsulated. 
Furthermore, size and surface modification of the particle is possible to target specific 
tissues and cells in the body. 
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1.4 Purpose and contents of this thesis 
A formulation strategy is the essential process of drug development. The main 
purpose of formulation is the realization of “easy to handle,” stabilization of payloads, 
control release, and improvement of absorption. These processes are directly linked to 
enhancement of efficacy, reduction of adverse effects, and improvement of usage. For 
example, the leuprorein acetate (a highly active agonist of luteinizing hormone-releasing 
hormone) deposit formulation is broadly used in clinical practice. Polymer microspheres 
(20 m in diameter) encapsulating leuprorein acetate achieve sustained release. Moreover, 
this formulation strategy is well tolerated for 1–3 months in patients with prostate 
cancer[13]. In this study, the author investigated nanoparticle delivery to injured tissue 
and formulation trial for the clinical application of the natural product extract apigenin. 
The aim was to examine the usefulness of nanosized formulation DDS in terms of 
targetability and enhancement of the efficacy of natural compounds. 
In Chapter 2, the author selected an appropriate liposome to deliver the drug in 
inflammatory regions using the monocrotaline (MCT)-induced pulmonary hypertension 
(PH) model—an inflammation model. In Chapter 3, the author evaluated the potential 
of liposome accumulation in the colitis model. In Chapter 4, the formulation approach 
of natural products for IBD using the DDS technology was proposed. Furthermore, the 
possibility for modification of the nanoparticle formulation was also discussed.  
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Chapter 2 Verify of the EPR effect in MCT-
induced lung injury rat model 
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2.1 Introduction 
Natural products are suitable tools for the treatment of inflammatory diseases. 
For example, treatment with apigenin, which is a plant-derived flavone, improved the 
symptoms of dextran sulfate sodium-induced colitis in a murine experimental model [11]. 
However, a limitation of natural products is their short residence in the body. For example, 
apigenin was removed within few hours after administration to rats [12]. Therefore, 
appropriate drug carriers are required to develop a treatment method for inflammatory 
diseases using natural products. To assess the targetability of nanoparticles against 
inflammatory disease, apart from IBD, the author also focused on the lung injury model. 
According to the World Health Organization-sponsored 2008 Dana Point Clinical 
Classification, PH is categorized into the following five groups based on etiologies and 
histopathological changes: (1) pulmonary arterial hypertension, (2) pulmonary venous 
hypertension due to left heart disease, (3) pulmonary hypertension due to lung 
disease/hypoxemia, (4) chronic thromboembolic pulmonary hypertension, and (5) PH due 
to unclear multifactorial mechanisms [13]. MCT is converted into monocrotaline pyrrole 
by dehydrogenation of the cytochrome P-450 enzyme in the liver. Subsequently, 
monocrotaline pyrrole induces damage to pulmonary artery endothelial cells and blood 
vessels [14]. This rodent model is regarded as a human PH mimicking model because of 
its similarities to humans in terms of the disease-developing process (i.e., vascular 
remodeling, proliferation of smooth muscle cells, endothelial dysfunction, upregulation 
of inflammatory cytokines, and right ventricle failure) [15]. Medications such as 
phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin 
analogues are available [13]. However, their therapeutic effects are limited, similarly to 
the existing medication for the treatment of IBD. One of the potential carriers is liposome, 
a drug carrier composed of lipid bilayers that can encapsulate natural products. The 
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residence of drugs in the body and bioavailability of natural products can be improved 
through encapsulation in liposomes [16].  
Size-dependent nanoparticle delivery is an essential element of DDS. The 
concept of the EPR effect was first reported by Maeda in 1986 [17], demonstrating that 
the nanosized particles (1–100 nm) passively leak from tumor blood vessels. In general, 
tumor blood vessels are characterized by immature vessel structure, owing to both tumor 
vessels having large pore sizes (300–400 nm). Moreover, the lack of a lymphatic system 
results in the passive accumulation of nanoparticles in the tumor. Abnormal 
vascularization is observed in tumor vessels and inflammation sites. Thus, high vascular 
permeability is predicted at these sites, suggesting higher accumulation of nanoparticles. 
He.C et al. indicated that the size and charge of a nanoparticle can influence the efficiency 
of its delivery in the tumor [18]. In addition, polyethylene glycol (PEG) coating is a 
common approach to avoiding aggregation of nanoparticles and the phagocytosis system 
[19]. In general, large-sized nanoparticles (>200 nm) are easily recognized by the 
reticuloendothelial system (RES). By contrast, small-sized nanoparticles (<20 nm) are 
susceptible to elimination through renal clearance. These findings suggested that 
nanocarrier design should be considered strategically. In Chapter 2, the possibility of site-
specific targeting based on the characteristics of the nanoparticle is described. 
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2.2 Materials and methods 
 2.2.1 Preparation of dye-labeled liposomes 
  FL-labeled liposome was manufactured as reported previously [20]. Liposomes 
with particle sizes of 80 and 180 nm were prepared using a thin-film hydration method. 
A mixture of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, NOF Corp., Tokyo, 
Japan), cholesterol (Chol, WAKO Pure Chemical Industries, Ltd.), and N-(carbonyl-
methoxypolyethyleneglycol 5000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
(DSPE-PEG, NOF Corp.) was dissolved in methanol and ethanol (1:1 v/v) with 1,1ʹ-
dioctadecyltetramethyl indotricarbocyanine iodide (DiR, Thermo Fisher Scientific, Inc., 
MA, USA). The solvent was evaporated to dryness, and the lipid film was further dried 
overnight. Subsequently, the film was hydrated in a 9% sucrose–water solution to obtain 
liposomes with a phospholipid concentration of 20 mM. The resultant liposomes were 
reduced in size through extrusion using a series of polycarbonate membrane filters. 
Liposomes with a 40 nm particle size were prepared using a microfluidic injection method. 
A mixture of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, NOF Corp.), 
Chol, and DSPE-PEG was dissolved in methanol and ethanol (1:1 v/v) with DiR. The 
dissolved lipids in the organic solvent were subsequently injected into a flow chemistry 
system (Syrris Ltd., Royston, UK). A 9% sucrose–water solution was also connected to 
the system. As the organic solvent in the lipid stream diffused and was diluted in the water 
stream, the lipids tended to assemble into liposomes in a micromixer chip. When the 
mixture reached equilibrium, stable liposomes were formed. The size distribution and 
zeta potential of the liposomes were analyzed through a dynamic light scattering method 
using a Zetasizer Nano analyzer (Malvern Instruments, Ltd., Malvern, UK).  
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2.2.2 Preparation of the MCT model 
MCT model was established as reported previously [20]. Male Wistar rats (7-
week-old, CLEA Japan, Inc., Tokyo, Japan) were anesthetized using subcutaneously 
administered isoflurane (3%) and monocrotaline (60 mg/kg, WAKO Pure Chemical 
Industries, Ltd., Tokyo, Japan) dissolved in saline. The dose of monocrotaline was set to 
60 mg/kg because it is generally used to induce pulmonary hypertension within 2 weeks 
17). The level of SP-D in the plasma was measured 2 weeks after the administration of 
monocrotaline using an SP-D enzyme-linked immunosorbent assay kit (Yamasa Corp., 
Chiba, Japan) to monitor the level of lung injury. 
 
2.2.3 Imaging analysis and gene expression analysis 
In vivo imaging analysis and gene expression analysis was performed as reported 
previously [20]. DiR-labeled liposomes (30–100 g/kg DiR) were intravenously 
administered to the MCT rat model through the tail vein 24 h prior to the measurements. 
Subsequently, tissue samples were placed into the light-tight chamber of the in vivo 
imaging system (IVIS) Spectrum imaging system (PerkinElmer, Inc., MA, US)and 
imaged ex vivo. The fluorescence intensity of the DiR-labeled liposome in the lung, liver, 
kidney, and blood was measured at excitation and emission wavelengths of 710 and 760 
nm, respectively. For the measurement of vascular permeability, fluorescein 
isothiocyanate (FITC) albumin (50 mg/kg FITC albumin, Sigma–Aldrich Corp., Inc., MO, 
USA) was intravenously administered 2 h prior to the measurement. Fluorescence was 
measured at excitation and emission wavelengths of 465 and 520 nm, respectively. For 
the measurement of the production of reactive oxygen species (ROS), the luminescent 
probe 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4-(2H,3H) dione, L-012 [21] 
(WAKO Pure Chemical Industries, Ltd.) was intravenously administered at 25 mg/kg 
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through the tail vein. The lung was isolated and imaged using the IVIS Spectrum ex vivo 
for 3 min. Data acquisition and analysis were performed using the Living Image Software 
(version 4.4., PerkinElmer, Inc.). The fluorescence and luminescence intensity of the 
region of interest (ROI) was quantified as average radiant efficiency. Gene expression of 
CD68 and GAPDH were measured and the Taqman primers/probes Rn01495634_g1 and 
Rn01775763_g1 (Thermo Fisher Scientific, Inc.) were used, respectively. 
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2.2.4 Data analysis for fluorescent imaging 
Data analysis was performed as previously [20]. An analysis of imaging data was 
performed using the Living Image Software (version 4.4., PerkinElmer, Inc.). Data of the 
fluorescence and luminescence intensity of the ROI was quantified as average radiant 
efficiency (p/s/cm²/sr or μW/cm²). The fluorescence of the liver, lung, and blood was 
normalized to the average fluorescence of the same tissue treated with the 40 nm PEG 
liposome to evaluate tissue change following accumulation in each tissue according to 
size and surface modification. Moreover, tissue fluorescence was normalized to that of 
the same tissue in normal rats to evaluate the change following accumulation of liposome 
and FITC albumin in the liver, kidney, lung, spleen and blood. Furthermore, the 
fluorescence of the lung was normalized to that of the lung in normal rats to evaluate the 
correlation between liposome accumulation in the lung and disease index. 
 
2.2.5 Statistical analysis 
Statistical analysis was performed as previously [20]. The Student's t-test was 
used to evaluate differences between two groups. Pearson's correlation coefficient was 
used to measure the strength of the association between the two groups, and the 
Bonferroni correction was used for multiple comparisons. p-Values < 0.05 were 
considered statistically significant. 
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2.3 Results 
 
2.3.1 Liposome manufacturing 
To deliver small molecule compounds to injury sites, the author developed a 
series of liposomes. The properties of liposomes are summarized in Table 2.1 
 
2.3.2 Detection of the inflammation site in the MCT rat model 
L-012, a luminescent probe for the detection of ROS (18), was administered to 
both MCT model and normal rats to detect the inflammatory response in the former. L-
012-derived lung luminescence was detected in the MCT model (Figure 2.1A) and 
increased to 264.9% versus that measured in the normal rats (Figure 2.1B). The level of 
CD68, one of the markers of macrophage gene expression, was measured in the MCT 
model. The expression of CD68 in the lung was significantly higher in the MCT model 
compared with that reported in the normal rats (Figure 2.1.C).  
  
2.3.3 Evaluation of liposome accumulation in the lungs of the MCT model 
Manufactured liposomes with different compositions and sizes were 
intravenously injected to MCT model and normal rats to identify the suitable formulation 
for efficient lung delivery. The fluorescent intensity in the tissue was normalized to the 
average value of the 40 nm liposome group (the values of the lung, liver, and blood were 
2.8 × 108, 4.3 × 108, and 3.5 × 107 [p/s/cm2/sr] / [µW/cm2], respectively). Twenty-four 
hours after administration, the liposomes did not accumulate in the lung tissue in normal 
rats. Unlike the 40 and 180 nm liposomes, the 80 nm liposome accumulated in the lung 
tissues of the MCT model rats. Long retention of all sizes of the PEG and 80 nm liposome 
was observed in the blood 24 h after administration (Figures 2.2A and 2.2B). Liposomes 
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with a 40 nm size exhibited higher accumulation in the liver than the 80 nm liposomes 
(170.5% of the 80 nm liposomes accumulated). Higher accumulation of 180 nm versus 
80 nm liposomes was observed in the spleen of injected rats (193.6% of the 80 nm 
liposomes) in both normal and MCT model rats. 
 
2.3.4 Correlation between liposome accumulation and vascular permeability in the 
lungs 
To prove the role of the EPR effect in liposome accumulation in the MCT model, 
the relationship between vascular permeability and liposome accumulation was 
investigated using the same rats. The fluorescence value of the 40 nm liposomes and FITC 
albumin leakage were assessed in the same sample (Figure 2.3A). The tissue fluorescence 
intensity was normalized to the average value measured in normal rats (the DiR 
fluorescence in the liver, spleen, kidney, lung, and blood was 1.8 × 108, 5.3 × 107, 4.5 × 
107, 8.6 × 107, and 3.7 × 107 [p/s/cm2/sr] / [µW/cm2], respectively. The intensity value of 
FITC fluorescence in the liver, spleen, kidney, lung, and blood was 2.9 × 108, 5.3 × 107, 
5.2 × 108, 2.3 × 108, and 4.1 × 107 [p/s/cm2/sr] / [µW/cm2], respectively). A higher level 
of the 40 nm PEG liposomes and significantly elevated vascular permeability were 
detected in the lungs of the MCT model rats compared with those reported in the normal 
rats. The accumulation of 40 nm PEG liposomes and FITC albumin was specific to the 
lung compared with the liver, spleen, kidney, and blood of the MCT model rats (Figure 
2.3B and 2.3C). A significant and positive correlation between vascular permeability and 
the accumulation of 40 nm PEG liposomes was observed (Figure 2.4). 
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Table 2.1 Composition and properties of liposomes. 
 
PEG, polyethylene glycol; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholin
e; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; Chol, cholesterol; DSPE-PEG,
 N-(carbonyl-methoxy polyethyleneglycol 5000)-1,2-distearoyl-sn-glycero-3-phospho
ethanolamine 
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Figure 2.1 Confirmation of the specific accumulation of FL-labeled liposomes at the 
lung injury site and relationship between FL-labeled liposome accumulation and 
macrophage marker in the MCT model. 
L-012-derived luminescent (A) image and (B) signals. L-012 (25 mg/kg) was 
intravenously administered 1 min prior to measurement (mean + standard deviation (SD), 
n = 2 and 5 (for normal and MCT groups, respectively)). (C) Expression of cluster of 
differentiation 68 (CD68) in the lungs of MCT model rats (mean + SD, n = 4 and 9 
(normal and MCT groups, respectively)). * p  0.05 vs. normal rats using Student's t-test.  
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Figure 2.2 Biodistribution of with/without PEGylated various size FL-labeled 
liposome Inflammation in the MCT model. 
(A) Fluorescent images of tissues imaged 24 h after the intravenous administration of 
the DiR liposome (100 g/kg, DiR) and (B) fluorescence of each tissue in the MCT model 
(mean + SD, n = 3 or 4 (PEG− or PEG+ groups, respectively). Values were normalized 
and expressed as a percentage (%) of the 40 nm PEG- group in the liver. *p  0.05 vs. the 
PEG− group using Student's t-test. 
DiR, 1,1ʹ-dioctadecyltetramethyl indotricarbocyanine iodide; Li, liver; Sp, spleen; K, 
kidney; Lu, lung; B, blood; MCT, monocrotaline-induced pulmonary hypertension; PEG, 
polyethylene glycol
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Figure 2.3 Relationship of vascular permeability and FL-labeled liposome 
accumulation in the MCT model. 
(A) Fluorescence image of the tissue distribution of 40-nm PEG liposome and FITC 
albumin in normal and MCT model rats, (B) distribution of DiR liposomes in normal and 
MCT model rats. DiR liposomes (30 g/kg, DiR) and FITC albumin (50 mg/kg) were 
intravenously administered 24 and 2 h prior to measurement, respectively, and (C) 
vascular permeability in normal and MCT model rats (mean + standard deviation (SD) < 
n = 4 or 9 (normal or MCT model group, respectively)). Values were normalized to the 
average values of normal rats. * p  0.05 vs. normal rats using Student's t-test. The p-
value for the correlation was calculated using Pearson's correlation coefficient. DiR, 1,1ʹ-
dioctadecyltetramethyl indotricarbocyanine iodide; Li, liver; Sp, spleen; K, kidney; Lu, 
lung; B, blood; MCT, monocrotaline-induced pulmonary hypertension model rat; PEG, 
polyethylene glycol. 
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Figure 2.4 Correlation between the accumulation of 40 nm PEG liposome and 
vascular permeability in the lungs. 
DiR liposomes (30 g/kg, DiR) and FITC albumin (50 mg/kg) were intravenously 
administered 24 and 2 h prior to measurement, respectively. Values were normalized to 
the average values of normal rats. 
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2.4 Discussion 
The results of this study indicated that PEGylated liposome accumulated in the 
injury site in the MCT model rats through the EPR effect. The author also demonstrated 
that the accumulation of liposome in the lungs of MCT model rats was significantly and 
positively correlated to vascular permeability. Enhancement of vascular permeability is 
an important mechanism for the delivery of liposomes in target tissues. Biodistribution 
studies of MCT model and normal rats were conducted after the intravenous 
administration of both FITC albumin and DiR-labeled 40 nm PEG liposome to evaluate 
the specificity of accumulation at the injury tissue. In comparison with the normal rats, a 
higher level of the 40 nm PEG liposomes and significantly enhanced vascular 
permeability were detected in the lungs of the MCT model rats. Conversely, there was no 
significant difference between the MCT model and normal rats in the other tissues. In 
addition, vascular permeability was significantly and positively correlated with the 
accumulation of liposomes. These findings suggest that elevation of vascular 
permeability is deeply involved in the mechanism of liposome accumulation.  
 For liposomes without PEG, our results suggest that long residence was achieved 
based on their size. The 80 nm DSPC-based liposome exhibited long retention in the 
blood of normal rats without accumulation in the liver and the spleen. In a previous study 
using normal mice, liposomes were distributed in the blood in a bell-shaped and size-
dependent manner. In addition, small-sized (<70 nm) liposomes accumulated in the liver, 
and an increase in the size of the liposome enhanced its accumulation in the spleen [22]. 
The liposome with a 110 nm size had long residence in the blood by avoiding 
accumulation in the liver and the spleen [22]. One of the reasons for the incorporation of 
the 40 nm liposome in the liver is the pore size in the liver sinus. The estimated pore size 
of liver sinus was 110 nm [23]. A liposome with a 180 nm size can be retained through 
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the use of a splenic sinusoidal filter that removes aged red blood cells [24]. A histological 
study indicated that large-size liposomes accumulated in red pulp, in which meshwork of 
reticular cell composition [25]. The present results regarding the accumulation of 40 nm 
and 180 nm liposomes is consistent with the evidence reported in previous studies.
 In this study, the author clarified that liposomes with long residence in the blood 
can accumulate in MCT model rats. Notably, the EPR effect can mediate the accumulation 
(Figure 2.3). Encapsulation of compounds in the liposome can lower systemic exposure 
and prolong their residence in target tissue. Focusing on the different lung disorder, these 
advantages were proved by previous studies. For example, liposomal formulation of 
amphotericin B for antifungal treatment achieved long circulation in the blood and 
prolonged the survival time without severe side effects in a mouse model of pulmonary 
aspergillosis [26] [27]. Therefore, encapsulation of drugs for nanosized liposomes can be 
a useful drug delivery system for the lungs of patients with PH. 
 Following the Chapter 2 results, the author evaluated the potential of liposome 
accumulation in the colitis model and the mechanisms in the Chapter 3. 
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Figure 2.5 Accumulation of the POPC/DSPC/Chol/DSPE-PEG liposome. 
A liposome can be delivered in inflamed tissue through the EPR effect. 
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Chapter 3 Liposome delivery in the 
inflammatory bowel disease model 
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3.1 Introduction 
 From the Chapter 2 results, specific accumulation of liposome at the lung injury 
site through the EPR effects was suggested. In this Chapter, the author evaluated the 
potential of liposome accumulation in the injury site of colitis model and the mechanisms. 
 IBD includes CD and UC, whose common symptoms are abdominal pain, 
diarrhea, and weight loss. The predilection site of CD is any part of the gastrointestinal 
tract with skipping lesions and cobblestone mucosa, from the mouth to the anus. The 
cause of IBD is poorly understood. Over 1 million and 2.5 million individuals in the USA 
and Europe, respectively, are suffering from IBD, which is currently a worldwide health 
concern [4]. In recent years, various treatment options have become available. However, 
conventional treatments are characterized by limitations, such as insufficient efficacy and 
the occurrence of severe adverse effects [28]. 
 Additionally, deep ulcers are observed in CD lesions in the colon walls. By 
contrast, UC lesions are limited to the large bowel with continuous uniform inflammation, 
extending only into the mucosa and submucosa. Recent studies suggested that patients 
with IBD are linked to a risk of developing colorectal cancer, and this risk increases by 
0.5–1.0% annually, 8–10 years after diagnosis [29]. A bimodal peak of age at onset is 
reported in CD: the 20–30-year age group and the 60–70-year age group. Meanwhile, the 
peak incidence age for UC is 20–30 years [30]. IBD exhibits the highest prevalence in 
North America (UC: 286 per 100,000 in the USA, CD: 319 per 100,000 in Canada) and 
Europe (UC: 505 per 100,000 in Norway, CD: 322 per 100,000 in Germany); conversely, 
it is less common in Asia [31]. It is presumed that the incidence rate of IBD tends to be 
higher in developing countries [31], with some studies suggesting that the “urban 
environment” is involved in the onset of IBD [2].    
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The main function of the digestive tract is the digestion of food and absorption 
of nutrients. However, recent studies emphasized their importance in the immune system. 
In other words, immune cells derived from gut immune organs, such as Peyer's patches 
and mesenteric lymph nodes, may be key players in the development of the immune 
system for the whole body [32]. In particular, immune cells at the intestinal epithelial 
barrier play a crucial role in the maintenance of gut environmental homeostasis [32]. The 
intestinal mucosal barrier involves a biological defense mechanism, which is regulated 
by mucosal immune cells against gut bacteria. Dendritic cells, macrophages and T cells 
are stimulated by over tens of thousands of gut bacteria [33]. These cells protect from 
bacterial invasion. In addition, antimicrobial peptides are secreted by intestinal epithelial 
cells. It is essential to undergo this process since infancy; microbiome diversity is 
associated with the development of the immune system [34]. However, the lack of 
microbiome diversity (i.e., dysbiosis) provokes imbalance of the intestinal environment 
[34]. The latest reports suggest that a wide variety of diseases (e.g., IBD, obesity, diabetes, 
depression, cancer, and allergy) are related to the gut microbiota [35]. In fact, dysbiosis 
links with host's condition deeply. Regarding IBD, overreaction of immune cells against 
gut bacteria and breakdown of the gut epithelial barrier are suspected causes of 
inflammation. Regulatory T cells are known as a modulator of the activated effector 
immune cells. Specifically, it has been reported that microbial metabolites, such as short 
chain fatty acids (acetic acid, propionic acid and butyric acid) produced by Bacteroides 
spp. promote the production of IL-10 and enhance the function of regulatory T cells. 
However, dysbiosis decreases Bacteroides spp. and migrates over to another bacterium 
dominant environment [36]. The host innate defense mechanism is important for 
maintaining intestinal epithelial barrier homeostasis. NOD-like receptor family pyrin 
containing (Nlrp) forms an inflammasome complex with an apoptosis-associated speck-
 31 
 
like protein containing a caspase recruitment domain and caspase-1, which promotes 
inflammatory response against pathogens at the mucosal barrier [37]. Activation of the 
inflammasome leads to the production of IL-18, IL-1b, and anti-microbials and defends 
the mucosal barrier against an invasion of gut microbacteria. This cycle is necessary for 
the development of the immune system in the mucosal barrier, and deficiencies in this 
cycle are related to the development of IBD.   
Therapeutic approaches against CD and UC are similar. Mesalazine (5-
aminosalicylic acid, 5-ASA) is currently the primary option for the treatment of these 
conditions. Some studies suggested that Mesalazine has the anti-oxidant and inhibitory 
effects of leukotrieneB4 [38]. In case of moderate inflammation, a synthetic 
adrenocortical hormone, such as prednisolone, is prescribed to the patients. For patients 
with advanced or refractory symptoms, biological products against IBD, such as 
adalimumab or infliximab, are selected. The pharmacological effects of these products is 
that they are known as monoclonal antibodies against TNF-In addition, the United 
States Food and Drug Administration-approved vedolizumab reacts with integrin 47 
(lymphocyte Peyer's patch adhesion molecule 1) and inhibits adhesion of the immune 
cells to the colon wall. As a last resort in the treatment of IBD, colectomy has been widely 
applied to patients with severe IBD. The latest therapeutic approach for patients with 
complex perianal fistula is stem cell therapy. Implantation of adipose-derived stem cells 
(Cx601) achieved clinical remission in a phase 3 trial. It is expected that Cx601 will be 
an alternative treatment to surgery. In the previous decades, transplantation of fecal 
microbiota has been investigated as a new safe treatment for IBD. The United States Food 
and Drug Administration approved this treatment against refractory infection with 
Clostridium difficile in 2013 [39]. Changing the diversity of the gut microbiome renders 
the improvement of the host intestinal environment possible. Thus, this method can also 
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be adopted for the treatment of IBD. Several meta-analyses and cohort studies have 
exhibited the efficacy of microbiota transplantation [39]. 
 In terms of adverse effects, 5-ASA drugs are safer than other types of drugs 
against IBD. However, allergic reactions were observed in 5%–10% of patients [28], and 
it is difficult to maintain complete remission after inflammatory recurrence. Regarding 
the efficacy of corticosteroids, 16% of patients were not cured, and 20%–30% had only a 
limited response [28]. In addition, long-term treatment with corticosteroids causes severe 
adverse effects. Therapy with anti-TNF-α drugs is a promising treatment option. However, 
anti-TNF-α drugs are costly and associated with the risk of carcinogenicity [28]. 
Considering efficacy, adverse effects and cost, there are several limitations in biological 
drug treatment; novel therapeutic indications for IBD are desired; and innovative 
medicines are warranted. As outlined above, IBD is affected by environmental factors, 
such as smoking, food, and the microbiome. Advanced therapies for IBD require a 
therapeutic strategy taking into consideration the environmental factors. In addition, the 
development of more target-specific treatments and concomitant use of several IBD 
medicines are necessary. The use of nanoparticles is one of the attractive DDSs to 
maximize efficacy and reduce the incidence of adverse effects. These formulations can 
improve the pharmacokinetic profiles and pharmacodynamic effects and reduce adverse 
effects.  
 The author explored whether liposomal formulations can specifically 
accumulate at the injury site of the colon and clarified the role of macrophages with 
liposomal uptake to determine the specific targetability of DDS. 
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3.2 Materials and methods 
3.2.1 Concanavalin A (ConA)-activated T-cell transfer IBD mouse model 
Con-A-activated T cell transfer IBD model was established as reported previously[40]. 
Animals 
 Female, 6-week-old BALB/cAnNCrlCrlj (BALB/c) mice were purchased from 
Charles River Laboratories Japan (Tokyo, Japan).  
Implantation 
 Lymphocytes were isolated from spleens of 7–9-week-old female BALB/c mice 
and incubated in a 2 × 106 cells/75 cm2 flask in a Roswell Park Memorial Institute 1640 
medium (Invitrogen, US) supplemented with 10% fetal bovine serum containing 1 μg/mL 
ConA (WAKO Pure Chemicals Industries, Japan) and 10 ng/mL interleukin (IL)-2 (R&D 
Systems, MN, USA) in an atmosphere of 95% air and 5% CO2 at 37°C for 72 h. CD4+ T 
cells were isolated from the incubated lymphocytes using the MACS CD4+ T-cell 
isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and intravenously 
transferred into recipient 6–8-week-old female C.B17/Icr-scid/scid Jcl (severe combined 
immunodeficiency [SCID]) mice (CLEA Japan, Inc.). Untreated SCID mice served as the 
controls.  
Follow-up 
 The development of colitis in SCID mice was followed by monitoring of stool 
consistency, and the diarrhea score was blindly recorded. The severity of diarrhea was 
scored using the following scale: 0 (untreated), 1 (normal), 2 (pasty and formed), 3 (pasty 
and unformed), and 4 (diarrhea). All mice were fed a standard diet (CE-2, CLEA Japan, 
Inc.) and had ad libitum access to drinking water. All experiments were approved by the 
Institutional Animal Care and Use Committee of Shonan Research Center, Takeda 
Pharmaceutical Company, Ltd. 
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3.2.2 FL (fluorescent)-labeled liposomes 
Nanoparticle formulation 
 FL-labeled liposome was manufactured as reported previously[40]. Liposomes 
labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide consisting 
of L-α-distearoyl- phosphatidylcholine (DSPC):cholesterol:polyethylene glycol PEG 
5000-L-α-distearoyl-phosphatidylethanolamine (DSPE):DiR = 50:45:5:0.5 (mol%) were 
manufactured using the extruder method. Free DiR was dispersed into a 9% sucrose 
solution and served as the control. The concentration of DiR was evaluated using a 
microplate reader (Molecular Devices, excitation: 748 nm, emission: 780 nm). The 
particles size was approximately 100 nm, measured using dynamic light scattering 
(Malvern). All formulations were manufactured at the Pharmaceutical Sciences 
Formulation Development of Takeda Pharmaceutical Company, Ltd. (Osaka, Japan). 
 
3.2.3 In vivo imaging analysis 
Fluorescence image 
 In vivo imaging analysis was performed as reported previously[40]. Twenty-six 
days after implantation, free DiR- (3 μg) or DiR-labeled (3 μg DiR equivalent) liposome 
was intravenously administered to the mice, and the diarrhea score was recorded. Prior to 
the FL imaging study, the mice were fasted for 18 h. Twenty-four hours after 
administration, the mice were euthanized, and whole blood samples were collected from 
the heart under anesthesia with isoflurane. Subsequently, the organs of each mouse were 
removed, and the colon tissues were weighed. The average radiant efficiency 
[p/s/cm²/sr]/[μW/cm²] was measured and calculated using the in vivo imaging system 
(IVIS) spectrum (PerkinElmer, USA) and the Living Image® software to evaluate the 
accumulation of FL-labeled liposomes.  
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3.2.4 Detection of ROS in the mouse colitis model 
Luminescence image 
 Twenty-eight days after implantation, L-012 (WAKO, Japan), a luminol-based 
chemiluminescent probe (20 mg/kg) for the detection of ROS, was intravenously 
administered to each mouse, and the diarrhea score was recorded. Five minutes after 
administration, the average radiance efficiency [p/s/cm²/sr] was measured under 
anesthesia with isoflurane and calculated using the IVIS spectrum and the Living Image® 
software. 
 
3.2.5 Confirmation of specific accumulation of FL-labeled liposomes at the injury 
site Dual fluorescence/luminescence image 
 Thirty days after implantation, DiR-labeled liposomes (3 μg DiR equivalent) 
were intravenously administered to untreated (score 0) and treated (score 4) mice. 
Twenty-four hours after administration, L-012 (WAKO, Japan), a luminol-based 
chemiluminescent probe (20 mg/kg) was intravenously administered to each mouse, and 
the diarrhea score was recorded. Five minutes after administration, the luminescence and 
fluorescence were measured and calculated using the IVIS spectrum in-vivo imaging 
system and the Living Image® software.  
 
3.2.6 Macrophage marker gene expression analysis in the colon 
Real-time PCR 
 Gene expression analysis was performed as reported previously[40]. Colon 
tissues were lyzed in the lysis buffer provided in the RNeasy mini kit (Qiagen, Germany). 
Total RNA was purified using the RNeasy mini kit according to the manufacturer’s 
instructions. Complimentary DNA was synthesized using reverse transcription (RT, 
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SuperScript® VILO™ cDNA synthesis kit, Life Technologies, USA) using isolated total 
RNA as a template. The levels of mRNA expression were measured through a quantitative 
real-time RT-polymerase chain reaction using the qPCR MASTER MIX (Nippon Gene, 
Japan) and ABI 7900HT (Life Technologies, USA). The target mRNA-specific primer 
and probe sets are listed in Table 1. Each mRNA expression was calculated using the 
ΔΔCt method according to the manufacturer’s instructions, and the mRNA expression 
levels of CD68, CD204, and F4/80 were normalized to those of hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) (internal control) (Table 3.1). 
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3.2.7 Statistical analysis 
Statistical significance test 
 Stastistical analysis was performed as reported previously[40]. For comparisons 
between three or more groups, a one-tailed Williams test or a two-tailed Shirley–Williams 
test was used. p-Values < 0.025 were considered statistically significant. The Spearman 
correlation coefficient was used to analyze the correlation between two groups. Statistical 
differences between two groups with p-values < 0.05 were considered significant. 
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3.3 Results 
3.3.1 Confirmation of the specific accumulation of FL-labeled liposomes at the colon 
tissue in the mouse colitis model 
 The author investigated the biodistribution of fluorescent-labeled liposomes 
after intravenous administration in a T-cell transfer mouse model of colitis to determine 
the advantages of DDS in IBD. The T-cell transfer model is a more important model of 
chronic colitis mediated by T cells, such as TH17, TH1, and regulatory T cells, compared 
with other mouse colitis models (Table 3.2) [41] [42]. Colon-wall thickening and 
elongation by swelling are observed in a colitis-severity-dependent manner (Figure 3.1). 
DiR was selected as the FL reagent. This reagent allows imaging with minimal intrinsic 
fluorescence owing to its longer excitation and emission wavelength. In addition, DiR 
can be combined with the lipid component of the liposome membrane owing to its 
hydrophobic property. Initially, the author evaluated the accumulation of FL-labeled 
liposomes in various disease states using IVIS. The results indicated that DiR-labeled 
liposomes accumulated in a colitis-score-dependent manner, although the DiR solution 
did not accumulate even in tissues of mice with severe colitis (Figures 3.2 and 3.3). In 
addition, the levels of fluorescence intensity were correlated with the colon weight and 
diarrhea score (Figures 3.4 and 3.5). 
 
3.3.2 Biodistribution analysis by IVIS 
 Strauch et al. reported that induction of colitis in germ-free mice did not result 
in disease progression [43]. Therefore, it is suggested that commensal gut bacteria 
function as antigens in this model; as can be seen from this model characteristic, localized 
inflammation in the colon tissue is assumed. The author assessed other organs (including 
the colon) in the mouse colitis model to confirm the biodistribution of the FL-labeled 
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liposomes in the whole body. The accumulation of the FL-labeled liposome in the 
inflamed colon was more specific compared with that observed in the other organs (Figure 
3.6).  
 
3.3.3 Simultaneous imaging of inflammation site detection and FL-labeled liposome 
accumulation  
 Subsequently, the colon injury site of mice with colitis was imaged by IVIS using 
L-012, a luminol-based chemiluminescent probe for the detection of ROS. L-012 can 
visualize sites of tissue injury, because elevation of immune-cell-derived production of 
ROS is observed in inflammation. The results of in vivo living imaging indicated that 
levels of luminescence intensity were significantly increased in mice with colitis versus 
normal mice (Figures 3.7 and 3.8). Furthermore, the lesion site in the colon tissue 
approximately corresponded to the accumulation of FL-labeled liposomes (Figure 3.9). 
Thus, the levels of luminescence intensity correlated with the accumulation FL-labeled 
liposomes (Figure 3.10). 
 
3.3.4 Identification of macrophage cellular uptake 
 Finally, the cells that uptake FL-liposomes were determined. In general, 
intravenously administered nanoparticles are taken up by the reticuloendothelial system. 
Therefore, the gene expression levels of three macrophage markers (i.e., CD68, CD204, 
and F4/80) were examined in colon tissues of mice at various disease states. All 
macrophage gene markers correlated with the accumulation of FL-labeled liposomes. 
These results suggested that FL liposomes may be efficiently delivered to macrophages 
(Figure 3.11). 
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 In addition, the results suggested that FL-labeled liposomes specifically 
accumulate to the injury site of the colon. Hence, this technology may be a novel attractive 
strategy for the development of drugs, such as macrophage-targeting drugs, against IBD. 
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Table 3.1 Three major types of mouse colitis models. 
 
Current experimental colitis animal models depend on pathological characteristics 
 
 
 
 
 
Model Inducer Route Evaluation
target
Mechanism of colitis
induction
DSS induced
colitis
Dextran sulphate
sodium
Oral Epithelial barrier
function
DSS is one of
mucopolysaccharide, it
provokes epithelial cell tight
junction damage with chelation
of divalent cation(Mg+ and
Ca+), followed by invasion of
proinflammatory intestinal
contents (e.g. bacteria and
their products) into lamina
propiria mucosae
TBNS induced
colitis
2,4,6-trinitrobenzene
sulfonic acid
Intrarectal Efficacy of anti-
cytokine
therapies
Rectal administration of the
hapten reagent TNBS induces
immunogenic reactions of CD
4+ T cell, macrophages, and
neutrophil  in the colon wall
Cell transfer
induced colitis
Lymphocytes
transplantation
Intravenously Immunoregulatio
n and regulatory
T cells
Naive T cell transfer model is
defined one of the important
model of chronic colitis
mediated by T cells such as
TH17, TH1and regulatory T
cells
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Figure 3.1 Quantification of the weight of mouse colon tissues in the colon tissue of 
mice with IBD at various disease states. 
A statistical analysis was performed between the DiR-labeled and liposome-treated 
mouse groups. Data are expressed as mean  SD (n = 5), ### p < 0.0005 by one-tailed 
Williams test. 
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Figure 3.2 Quantification of the weight of mice colon tissues in the colon tissue of 
mice with IBD at various disease states. 
Biodistribution analysis of the DiR solution- or DiR-labeled liposomes by IVIS imaging 
in the colon tissue of mice with IBD at various disease states. DiR solution-treated mice 
(dotted lines, n = 1) and DiR-labeled liposome-treated mice (solid line, n = 5).  
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Figure 3.3 Quantification of luminescence intensity in the colon tissue of mice with 
IBD at various disease states. 
A statistical analysis was performed between the DiR-labeled and liposome-treated 
mouse groups. Data are expressed as mean  SD (n = 5). ### p < 0.0005 by one-tailed 
Williams test. 
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Figure 3.4 Correlation between tissue weight and fluorescence intensity in the colon 
tissues of mice at various disease states. 
A statistical analysis was performed between the DiR-labeled and liposome-treated score 
0–4 mice groups (n = 5 each). ### p < 0.001 by Spearman correlation. 
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Figure 3.5 Correlation between the diarrhea score and fluorescence intensity in the 
colon tissues of mice at various disease states. 
A statistical analysis was performed between the DiR-labeled and liposome-treated score 
0–4 mouse groups (n = 5 each). ### p < 0.001 by Spearman correlation. 
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Figure 3.6 Assessment of the tissue biodistribution of the DiR-labeled liposome in 
mice with IBD at various disease states. 
Fluorescence in each tissue of score 0 mice treated with the DiR solution was defined as 
100% (n = 1, each). 
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Figure 3.7 Optical imaging of ROS detection and accumulation of the DiR-labeled 
liposome in score 0, 2, and 4 mice with IBD. 
A living image of ROS production by IVIS. Data are expressed as mean  SD (n = 5). 
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Figure 3.8 Quantification of luminescence intensity using the IVIS software in score 
0, 2 and 4 mice with IBD. 
Data are expressed as mean  SD (n = 5) # p < 0.05 by two-tailed Shirley–Williams test. 
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Figure 3.9 Luminescence for the detection of ROS (left) and fluorescence for DiR 
(right) images of score 0 versus score 4 mice. 
Data were taken by luminescence or fluorescence setting in IVIS (n = 1, each). 
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Figure 3.10 Correlation between the production of ROS and fluorescence intensity 
in the colon tissues of mice. 
A statistical analysis was performed between the DiR-labeled and liposome-treated score 
0–4 mouse groups (n = 4 each). ### p < 0.001 by Spearman correlation. 
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Figure 3.11 Correlation between macrophage markers (CD68, CD204 and F4/80) 
and fluorescence intensity in the colon tissues of mice. 
A statistical analysis was performed between the DiR-labeled and liposome-treated score 
0–4 mouse groups (n = 4, each). # p < 0.05 and ## p < 0.01 by Spearman correlation. 
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3.4 Discussion 
 The author investigated the biodistribution of FL-labeled liposomes after 
intravenous administration in the IBD mouse model to explore the advantage of 
nanoparticles. Recent studies using imaging methods indicated that the intravenous 
administration of 200 nm-sized nanoparticles results in their accumulation in the colons 
of mice with colitis. Watanabe et al. demonstrated that ~110 nm is the optima size for 
targeting the colon and that dextran sulfate sodium (DSS) induced colitis in the mouse 
model [44]. The three major types of mouse colitis models are presented in Table 3.2. It 
has been suggested that the DSS-induced colitis mouse model poorly mimics human IBD 
because DSS induces breakdown of the mucosal barrier without crucial immune cell 
involvement. In chronic IBD, more complicated pathological conditions occur, such as T 
helper 17 cells and regulatory T cells [45]. Therefore, it is important for one to select the 
most appropriate animal model to evaluate the relationship between nanoparticles at the 
accumulation and injury sites. In this study, the author detected a strong correlation 
between the accumulation of FL-labeled liposomes and colitis disease state in the T-cell 
transfer IBD mouse model. In typical experimental IBD animal models, disease severity 
is often correlated with the activity of myeloperoxidase (MPO) and higher levels of pro-
inflammatory cytokines. MPO activity can be used as a surrogate marker of inflammation 
[46]. MPO plays a role as a major enzymatic catalyst of lipid peroxidation, contributing 
to the production of ROS in conjunction with the nicotinamide adenine dinucleotide 
phosphate-oxidase enzyme. Intravenously injected liposomes and micelles are recognized 
by macrophages and are eventually trapped by the RES in the liver, spleen, and lymph 
nodes [47]. The author demonstrated that the fluorescent intensity of the FL-labeled 
liposome was positively correlated with the levels of macrophage marker gene expression. 
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Recently, macrophages were categorized into two types: inflammatory (M1) and 
resolving (M2) macrophages. M1 cells are thought to play a role in prototypic 
inflammatory response, whereas M2 cells are thought to play a role in inflammation 
resolution and tissue remodeling [48]. Hoppstädter J et al. suggested that nanoparticle 
(<41 nm) uptake by M2 macrophages was enhanced compared with that by M1 
macrophage. Moreover, these findings were not observed in micro-sized particles [49]. 
In the gastrointestinal epithelial barrier, M2 macrophages play a crucial role in the host 
gut environment. M2 macrophages downregulate excessive anti-inflammatory reaction in 
response to bacterial products, such as short-chain fatty acids [50]. The characteristics of 
these M2 macrophages can be adopted in the treatment strategy against IBD. In other 
words, the activation of drug-encapsulating nanoparticles by M2 macrophages is an 
attractive formulation for the improvement of IBD treatment. However, further research 
is warranted to identify the type of macrophages that uptake nanoparticles and determine 
the contribution of other types of immune cells (e.g., lymphocytes). In conclusion, the 
nanoparticle formulation strategy is promising for the treatment of cancer and other 
conditions, such as IBD.  
 Apigenin is a flavone compound abundantly found in plants (e.g., 
Dracocephalum kotschyi, Matricaria recutita L, and Olea europaea). Its antioxidant, 
anti-inflammatory, and anti-cancer activities have been previously stated. The study 
conducted by Sadraei et al. indicated that apigenin has an inhibitory effect on 
myeloperoxidase activities in acetic-acid-induced colitis mouse models, providing similar 
efficacy to that of prednisolone [51]. Additionally, Isoda et al. demonstrated that apigenin, 
oleuropein, and luteolin in Picholine olive oil inhibit several important inflammatory 
signaling pathway molecules, such as AKT and TNF, in a rat basophilic leukemia mast 
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cell line [52]. Notably, this group demonstrated the anticancer effect of ethanolic extracts 
containing tyrosol, hydroxytyrosol, oleuropein, rutin, quercetin, and glucoside forms of 
luteolin and apigenin from olive fruitsin human colon cancer cell lines [53]. Moreover, 
Radulovic et al. suggested that apigenin improves microbiome diversity via an 
inflammasome independent pathway in dextran sulfate sodium-induced mouse colitis. 
Collectively, natural products (e.g., polyphenols and flavonoids) prevent the functional 
impairment of intestinal epithelial cells, concomitant with inflammation of the lamina 
propria through direct anti-inflammatory effects and indirect therapeutic effects, 
including improvement of the gut microbiome environment. In Chapter 4, the author 
presents a feasibility study for the manufacturing of a natural product-encapsulating 
nanoparticle.  
 Following the contents of Chapter 1,2, and 3, the author tried manufacturing of 
nanoparticle encapsulated natural product derived compound as apigenin nanoparticle in 
the Chapter 4. In addition, the inhibitory effect of this formulation was investigated in 
mouse macrophage cell line.  
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Chapter 4 Formulation approach for natural 
products in IBD 
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4.1 Introduction 
 In this Chapter, the author proposed novel formulation optimization strategies 
for natural products using DDS. Although natural products possess diverse 
pharmacological activities, occasionally, utilization as a bioactive substance is limited 
owing to the lack of efficacy, pharmacokinetic problems, and adverse effects. Since 
apigenin and luteolin exhibit poor solubility and/or low oral bioavailability, significant 
pharmacokinetic improvement will be expected by the formulation approach.  
 Owing to the hydrophobicity of apigenin, the liposomal or PLGA (Poly lactic-
co-Glycolic Acid) formulation is considered a powerful option for formulation 
optimization. Similarly, rosmarinic acid is an alcohol-soluble compound, and liposomal 
formulation is a possible approach. In addition, rosmarinic acid contains a carboxylic acid, 
which is represented by the general formula R-COOH. The carboxylic acid makes it 
possible to combine various kinds of hydrophobic groups. In case of water-insoluble 
compounds, such as oleuropein, a different approach is required. For example, the water 
in oil water method is an effective manufacturing method for water-insoluble compounds 
in nanoparticle formulation. 
 In recent years, nanoparticle formulation approaches for these natural products 
have been investigated by several studies. These research studies suggested that apigenin 
and luteolin nanoparticles (liposome and PLGA) for the specific targeting of 
inflammation sites and cancer are promising. The in vitro and in vivo stabilities of these 
nanoparticles are sufficient for these evaluations [54]. Indeed, numerous studies have 
reported apigenin-, luteolin-, and rosmarinic acid-encapsulating nanoparticles (Table 4.1). 
These reports targeted a wide range of diseases and formulations. The versatility of 
nanoparticles was suggested in this study. Moreover, modification of the nanoparticle 
surface and encapsulation of multiple ingredients is possible depending on the properties 
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of the materials. Theoretically, various antibodies, peptides, and nucleic acids can be 
selected as materials for surface modification. Moreover, a couple of natural products can 
be selected as payload. This attractive approach realizes novel formulation manufacturing, 
such as both apigenin- and luteolin-encapsulating surface-modified nanoparticles with 
available therapeutic antibodies (e.g., TNF-antibody) and/or peptides (e.g., IL-22).  
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Table 4.1 Current formulation approaches against natural compounds. 
Natural products Oral 
Intravenously or 
intraperitoneal 
Inhalation or 
intranasal 
in vitro 
Apigenin 
(C) 
Nanosuspensio
n[55] 
(C) PLGA[56] 
(IM) Bovine 
serum albumin 
nanoparticles 
[57] 
(C)The apigenin-loaded sodium 
hyaluronate nano-assemblies [58]   
(I) Silver nanoparticles [59]  
(IM) Biodegradable polymer carrier 
[60] 
(C) PLGA 
nanoparticles[55] 
(IM) Degradable poly (apigenin) 
polymer [61] 
(C) PLGA [62] 
(C)Apigenin loaded lipid nanocapsules 
[63] 
luteolin - 
(C) Luteolin-loaded 
micelles [64] 
- 
(C,IM) Gold nanoparticles [65] (C) Water-soluble 
polymer-encapsulated 
nano-luteolin [66] 
(C) Monomethoxy 
poly(ethylene glycol)-
poly(e-caprolactone) 
micelles to encapsulate 
luteolin [67] 
(C,I) mPEG-luteolin-silver 
nanoparticles [68] 
Rosmarinic acid - - 
(N) Optimized 
rosmarinic 
acid-loaded 
solid lipid 
nanoparticles 
using tween 80 
[69] 
(N)Rosmarinic acid- and curcumin-
loaded polyacrylamide-cardiolipin-
poly(lactide-co-glycolide) nanoparticles 
with conjugated 83-14 monoclonal 
antibody [70] 
(N)Rosmarinic acid-loaded 
polyacrylamide-chitosan-poly(lactide-
co-glycolide) nanoparticles and surface 
DSPE-PEG(2000) nanoparticles [71] 
(IM) Solid nanoparticles produced with 
two different waxes loaded with 
rosmarinic acid [72] 
(IM) Rosmarinic acid loaded chitosan 
nanoparticles [73]  
(MB) Solid nanoparticles produced with 
two different waxes loaded with 
rosmarinic acid [74] 
 
* The words in parentheses are targeted diseases; C:cancer, I:infection, IM:inflammation, 
N:nurve system and MB:microbiome 
 
 
 60 
 
4.2 Materials and methods 
4.2.1 Nanoparticle manufacturing 
 Apigenin (>98% purity, TOKYO CHEMICAL INDUSTRY CO., LTD., Ja
pan), 1,2-Dimyristoyl-rac-glycerol (GM-020, NOF CORPORATION, Japan), 1,2-Di
palmitoyl-sn-glycero-3-phosphocholine (DPPC, NOF CORPORATION, Japan), Cho
lesterol(Avanti Polar Lipids, Inc. USA) and 1,2-Dioleoyloxy-3-trimethylammonium 
propane (DOTAP, NOF CORPORATION, Japan) were used as materials of nano
particles. apigenin was dissolved in 90% ethanol (EtOH), 10% water at 172 g/
ml with lipids at mixing molar ratio shown in Table 4.2. 1.5 ml of apigenin an
d lipid mixturewas mixed with 7.5 ml of 10 mM borate buffer pH 9 in a micro
fluidic mixer NanoAssemblr (PRECISION NANOSYSTEMS, USA) to form nano
particles. Resulting nanoparticle dispersion was dialyzed with dialysis membrane 
of MWCO 20 k against PBS for 24 hours at 4 ℃. The nanoparticle was stored 
at 4 ℃ before use. apigenin concentrations of each nanoparticle formulation were
 determined by colorimetric analysis of measuring optical absorbance at 405 nm 
after dissolving in 10% borate EtOH solution. Scattered light intensity, diameters 
and zeta-potential of nanoparticles were measured by static, dynamic and electrop
horetic light scattering analysis method with Zetasizer Nano ZS (Malvern Panalyt
ical, UK). 
 
 
 
 
 
 
 61 
 
 
 
 
 
 
Table 4.2 Components of nanoparticles. 
  
① Apigenin 
nanoparticle 
② Empty 
nanoparticle 
③ DOTAP(-) 
nanoparticle 
④ Apigenin 
solution 
Apigenin 5 0 5 5 
GM-020 2 2 2 0 
DPPC 33 33 33 0 
Cholesterol 30 30 30 0 
DOTAP 30 30 0 0 
 
Component ratio of each formulation are shown as percentage by moles (Mol%). 
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4.2.2 Gene expression analysis of inflammation related marker in LPS-stimulated 
RAW264.7 cell line 
 RAW264.7 cell line (American Type Culture Collection, USA) was seeded at a 
density of 2 × 105 cells/1 well/12 well plate in Dulbecco's Modified Eagle's Medium 
(Invitrogen, US) with 10% fetal bovine serum containing 100 U Penicillin-Streptomycin 
(Invitrogen, US). All formulations were added with cell seeding at the same time and 
incubated in an atmosphere of 95% air and 5% CO2 at 37°C for 24 h. Cells were 
stimulated by LPS (5ng/mL) for 4h and lysed at in the lysis buffer provided in the RNeasy 
mini kit (Qiagen, Germany). Total RNA was purified using the RNeasy mini kit according 
to the manufacturer’s instructions. Complimentary DNA (cDNA) was synthesized using 
reverse transcription (RT, SuperScript® VILO™ cDNA synthesis kit, Life Technologies, 
USA) using isolated total RNA as a template. The mRNA expression levels were 
measured using quantitative real-time RT-polymerase chain reaction using the 
quantitative PCR MASTER MIX (Nippon Gene, Japan) and ABI 7900HT (Life 
Technologies, USA) with the target mRNA specific primer and probe sets listed in Table 
4.3 Each mRNA expression level was calculated using the 2−ΔCt method according to the 
manufacturer’s instruction, and mRNA expression levels of IL-1, TNF-, Nlrp3, IL-6 
and GAPDH were normalized to mRNA expression levels as an internal control.  
 
4.2.3 Statistical analysis 
 For two groups comparison, Student's t-test or Aspin-welch test was used, P-
values < 0.05 were considered statistically significant.  
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4.3. Results 
4.3.1 Confirmation of solubility in EtOH and nanoparticle formulation 
 Since apigenin aggregates in aqueous solutions, it is difficult to administer 
systemically for in vivo study and clinical use. To investigate aggregation behavior of 
apigenin in polar solvent, apigenin was dissolved in EtOH and then diluted with varied 
ratio of water, followed by scattered light intensity measurement to detect formation of 
aggregates. Apigenin could be dissolved in 100% EtOH completely, while precipitated at 
EtOH concentration lower than 30% (Figure 4.1). Based on this result, four nanoparticle 
formulations were manufactured by ethanol dilution method (Figure 4.2). 
 A cationic lipid DOTAP was selected as one of components of nanoparticle to 
facilitate nanosized co-precipitation of anionic apigenin with the other nanoparticle 
components. As a result, Z-average diameter of apigenin containing nanoparticle was 37 
nm with polydispersity index 0.345, while Z-average diameter of apigenin dispersion 
without nanoparticle components was as large as 1632 nm and polydispersity index 1, 
almost out of the range of size distribution measurement by dynamic light scattering 
method (Table 4.4). Regarding a formulation without DOTAP, neither Z-average diameter 
nor polydispersity index indicated deposition of apigenin, however, significant amount of 
deposition was observed in the bottom of test tube by visual inspection (Figure 4.2). 
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Figure 4.1 Apigenin solubility in various ethanol concentration. 
Apigenin was dissolved in EtOH and diluted with varied ratio of water.  
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Table 4.2 Formulation characteristic parameter. 
Sample Z-average diameter (nm) Polydispersity index 
① Apigenin nanoparticle 37 0.345 
② Empty nanoparticle 35 0.33 
③ DOTAP(-) nanoparticle 60 0.156 
④ Apigenin solution 1632 1 
Z-average diameter and polydispersity index of each formulation. 
 
 
 
 
 
 
 
 
 
 
 
 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Sample appearance in the 15mL tube at 1 week after manufacturing. 
Amount of deposition was observed in the bottom of test tube by visual inspection in ③ 
and ④. 
 
 
 
 
 
④Apigenin 
solution 
③DOTAP(-) ②Empty 
nanoparticles 
① Apigenin 
nanoparticles 
 67 
 
4.3.2 Enhanced anti-inflammatory effect by apigenin nanoparticles in LPS-
stimulated RAW264.7 cell line 
 Our preliminary studies demonstrated that apigenin could dissolve completely in 
100% Dimethyl Sulfoxide (DMSO) solution which is one of the strongest organic 
solvents. However apigenin made precipitates under low DMSO concentration condition 
such as buffer solution and basal medium, which means therapeutic effect of apigenin 
could not be estimated exactly. In this study, apigenin solution made precipitates in the 
synthesis process as the author expected, on the other hand apigenin nanoparticle endured 
the use in evaluation. IL-1 and TNF- are typical inflammatory mediators in IBD, in 
addition IL-6 drives Th17 differentiation of naïve T cells, it exacerbates inflammation in 
the gut[43]. Nlrp3 inflammasome is also deeply involved in IBD disease progression, 
previous study suggested that suppressing Nlrp3 activation prevented gut 
inflammation[43]. Apigenin nanoparticle had a stronger inhibitory effect on these gene 
expression levels compared with apigenin solution significantly (Figure 4.3). 
Unexpectedly, empty nanoparticle in itself inhibited elevation of LPS-induced thesegene 
expression levels strongly, it was suggested that this nanoparticle materials have potent 
anti-inflammatory effect in this model. 
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Figure 4.3 Anti-inhibitory effect of apigenin nanoparticle on LPS stimulated 
RAW264.7 cell line. 
Data are expressed as mean + SD (n = 3) $ p < 0.05 and $$$ p < 0.001 by Student’s t-test 
or Aspin-welch t-test. Data are expressed as mean + SD (n = 3) # p < 0.05, ##p < 0.01 
and ###p < 0.001 by Student’s t-test or Aspin-welch t-test. 
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4.4 Discussion 
 Previous reports suggest that apigenin could be encapsulated successfully such 
as liposome, lipid nanocapsule and polymeric nanocapsule [75]. To realize clinical 
apigenin indication with DDS, formulation approach is necessary, especially strategy for 
overcoming hydrophobicity against aqueous solution is important. As described, this 
formulation with DOTAP could avoid precipitation, it kept in culture medium. The most 
likely mechanism of nanoparticle assembly is reaction between de-protonated anionic 
apigenin at pH9 and cationic DOTAP, thus apigenin-DOTAP co-precipitates in 
nanoparticle (Figure 4.4).  
 It is presumed that cationic lipid such as dimethyldioctadecylammomium 
bromide (DDAB), DOTAP, 3-tetradecylamino-N-tert-butyl-N′-tetradecylpropionamidine 
(DiC14-amidine), dimyristoyltrimethylammonium propane (DMTAP) or 
dimethylaminoethanecarbamoyl cholesterol (DC-Chol) has anti-inflammatory activity in 
vitro or in vivo model[76]. Filion et al. proved that these cationic lipids inhibited swelling 
of footpad inflammation induced by carrageenan or by sheep red blood cell challenge, 
moreover they suggested that these mechanism might be involved in blockade of IL-6 
and TNF-a in the cytoplasm after macrophage phagocytosis [77]. Concentration of 
cationic lipid in this article corresponded fairly closely to cationic lipid of this 
nanoparticle concentrations. Elouahabi A et al. demonstrated that free diC14-amidine 
liposome injected to mice may be preferentially taken up by macrophages, resulting in a 
decrease in their ability to respond to stimulation by the CpG motifs contained in diC14-
amidine/protamine/pCMV-luc complex and consequently to secrete TNF-α[76]. As was 
the studies for previous reports, our studies suggested that cationic lipids are potent 
inhibitors of the LPS-induced inflammatory response through macrophage phagocytosis. 
The mechanism of anti-inflammatory effect of cationic liposome may be involved in 
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protein kinase C (PKC) activity. Previous reports suggest that one of the cationic lipid, 
amphiphiles possesses inhibitory effects against PKC [78]. Hence, it is hypothesized that 
cationic liposome block the molecule of downstream signaling pathway of PKC, such as 
NFB activation, it leads downregulation of TNF-, IL-1, IL-6 and NO. Meanwhile, it 
is seemed that apigenin has several important inflammatory signaling pathway molecules 
such as AKT and TNF as above[52]. Besides these effects, inhibition of inflammasome 
mediated pathway is considered as one of the blockade mechanisms of macrophage 
activation[79]. Here, the author proved that apigenin inhibited Nlrp3 gene expression 
levels in LPS-stimulated RAW264.7 cell line model. In fact, apigenin its own possesses 
inhibitory effects against inflammasome through inhibition of the oligomerization of 
apoptosis-associated speck like protein containing a caspase recruitment domain [37], 
nanoparticle formulation make it possible to enhance the effect sufficiently because 
nanoparticles are uptaken by macrophage through phagocytosis (Figure 4.6). In 
consideration of our results, anti-inflammatory effect of apigenin could not be assessed 
exactly because cationic lipid nanoparticles have powerful anti-inflammatory effects, thus 
it was difficult to judge whether additive or synergistic effect could be achieved or not. 
Nevertheless, this formulation made it possible to be sufficient totreat in vitro and in vivo 
study. Additional work is needed to show proof of concept. 
 Inflammasome and these inflammatory cytokine activation are associated with 
increased risk for the development of several disorders besides IBD, such as 
erythematosus, rheumatoid arthritis and diabetes [80], these findings suggests that 
apigenin nanoparticle is attractive therapeutic option for these refractory diseases. 
In conclusion, apigenin nanoparticle could be manufactured successfully, the 
nanoparticles showed strong efficacy. According to our results, cationic lipid on its own 
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has powerful anti- inflammatory effects, these findings suggest that nanoparticle 
encapsulated natural product can be a promising formulation for inflamed tissues. 
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Figure 4.4 Diagram of nanoparticle assembly with apigenin and DOTAP. 
Reaction between de-protonated anionic apigenin at pH9 and cationic DOTAP. 
 
 
 
 
 73 
 
 
 
 
 
Figure 4.5 Hypothesis of Mechanism of Inhibitory Effect of DOTAP on NO and 
TNF Production. 
Cationic lipid block the molecule of downstream signaling pathway of PKC, such as 
NFB activation, it leads downregulation of TNF-and NO. 
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Figure 4.6 Hypothesis of mechanism of strong effect of Apigenin liposome. 
Nanoparticles uptake by macrophage through phagocytosis enhance the anti-
inflammatory effect sufficiently due to both blockade of downstream signaling pathway 
of PKC by cationic liposome and inhibition of important inflammatory signaling such as 
AKT and TNF.  
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Chapter 5 General conclusions 
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 Natural products such as polyphenol or flavonoids derivatives have an inhibitory 
effect of abnormal immune cells activation in colitis tissue, it leads mucosal epithelial 
barrier protection. Additionally, these ingredients have a potential to improve intestinal 
microbiome diversity, consequently bacterial metabolites play an important role of 
keeping environmental homeostasis. These findings suggest that natural products have a 
potential to ameliorate colon inflammation.  
 In Chapter 2, the author selected appropriate liposome to deliver for 
inflammatory region using MCT model, and proved that liposome accumulation was 
correlated with severity of vascular permeability, in other words, this liposome 
accumulated in injured tissue through EPR effect. In Chapter 3, the author evaluated 
potential to accumulation of liposome for colitis model. The results showed that specific 
accumulation at the colon was observed in T cell transfer IBD mouse model, liposome 
delivery in accordance with pathological severity was demonstrated. Moreover, liposome 
accumulation was correlated with macrophage related gene marker expression levels, it 
is suggested that this liposome can be a promising formulation for delivery to the injured 
IBD tissue specifically. In Chapter 4, the formulation approach of natural products for 
IBD was proposed using DDS technology, moreover the possibility for modification of 
nanoparticle formulation was suggested.  
 In conclusion, important findings for the development of the future treatment for 
IBD based on environmental changes were obtained, moreover natural product 
encapsulated therapeutic nanoparticles for social implementation was manufactured 
successfully. This formulation strategy might be able to give new treatment options for 
inflammatory disease patients. 
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